Overview

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

Status:
Completed
Trial end date:
2019-08-07
Target enrollment:
0
Participant gender:
All
Summary
The purpose of study is to confirm the efficacy of DWP14012 Xmg, Once daily, compared to esomeprazole 40mg in patients with erosive gastroesophageal reflux disease.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Treatments:
Esomeprazole
Criteria
Inclusion Criteria:

- Adults between 20 and 75 years old based on the date of written agreement

- Those who have been diagnosed with erosive gastroesophageal reflux disease(EGRD) of LA
Grade A-D on the upper gastrointestinal endoscopy

- Those who experienced symptoms of heartburn or acid regurgitation within the last 7
days

Exclusion Criteria:

- Those who have undergone gastric acid suppression or gastric, esophageal surgery

- Those who with clinically significant liver, kidney, nervous system, respiratory,
endocrine, hematologic, cardiovascular, urinary system disease